119 related articles for article (PubMed ID: 27170011)
1. Olodaterol for the treatment of asthma.
Cazzola M; Rinaldi B; Lucà G; Ora J
Expert Opin Investig Drugs; 2016 Jul; 25(7):861-6. PubMed ID: 27170011
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
[TBL] [Abstract][Full Text] [Related]
3. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review.
Melani AS
Expert Opin Pharmacother; 2018 Oct; 19(14):1603-1611. PubMed ID: 30311516
[TBL] [Abstract][Full Text] [Related]
4. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.
van Noord JA; Smeets JJ; Drenth BM; Rascher J; Pivovarova A; Hamilton AL; Cornelissen PJ
Pulm Pharmacol Ther; 2011 Dec; 24(6):666-72. PubMed ID: 21839850
[TBL] [Abstract][Full Text] [Related]
5. Next generation beta adrenoreceptor agonists for the treatment of asthma.
Crisafulli E; Frizzelli A; Fantin A; Manco A; Mangia A; Pisi G; Fainardi V; Alfieri V; Aiello M; Bertorelli G; Chetta A
Expert Opin Pharmacother; 2017 Oct; 18(14):1499-1505. PubMed ID: 28891349
[TBL] [Abstract][Full Text] [Related]
6. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol.
Casarosa P; Kollak I; Kiechle T; Ostermann A; Schnapp A; Kiesling R; Pieper M; Sieger P; Gantner F
J Pharmacol Exp Ther; 2011 Jun; 337(3):600-9. PubMed ID: 21357659
[TBL] [Abstract][Full Text] [Related]
7. The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.
Lee HW; Kim HJ; Lee CH
Br J Clin Pharmacol; 2017 Jun; 83(6):1166-1175. PubMed ID: 27957746
[TBL] [Abstract][Full Text] [Related]
8. β2-agonist therapy in lung disease.
Cazzola M; Page CP; Rogliani P; Matera MG
Am J Respir Crit Care Med; 2013 Apr; 187(7):690-6. PubMed ID: 23348973
[TBL] [Abstract][Full Text] [Related]
9. Bronchoprotection by olodaterol is synergistically enhanced by tiotropium in a guinea pig model of allergic asthma.
Smit M; Zuidhof AB; Bos SI; Maarsingh H; Gosens R; Zaagsma J; Meurs H
J Pharmacol Exp Ther; 2014 Feb; 348(2):303-10. PubMed ID: 24307202
[TBL] [Abstract][Full Text] [Related]
10. Ultra-LABAs for the treatment of asthma.
Cazzola M; Rogliani P; Matera MG
Respir Med; 2019 Sep; 156():47-52. PubMed ID: 31425937
[TBL] [Abstract][Full Text] [Related]
11. ▼Olodaterol--another LABA for COPD.
Drug Ther Bull; 2015 Apr; 53(4):42-5. PubMed ID: 25858815
[TBL] [Abstract][Full Text] [Related]
12. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium sustains the anti-inflammatory action of olodaterol via the cyclic AMP pathway.
Costa L; Roth M; Miglino N; Keglowich L; Zhong J; Lardinois D; Tamm M; Borger P
Pulm Pharmacol Ther; 2014 Feb; 27(1):29-37. PubMed ID: 24269928
[TBL] [Abstract][Full Text] [Related]
14. Characterization of long-acting beta₂-adrenergic agonists utilization in asthma patients.
Kaplan S; Zhou EH; Iyasu S
J Asthma; 2012 Dec; 49(10):1079-85. PubMed ID: 23106094
[TBL] [Abstract][Full Text] [Related]
15. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice.
Tamm M; Richards DH; Beghé B; Fabbri L
Respir Med; 2012 Dec; 106 Suppl 1():S9-19. PubMed ID: 23273165
[TBL] [Abstract][Full Text] [Related]
16. Striving for optimal bronchodilation: focus on olodaterol.
Incorvaia C; Montagni M; Makri E; Riario-Sforza GG; Ridolo E
Int J Chron Obstruct Pulmon Dis; 2016; 11():439-44. PubMed ID: 27042036
[TBL] [Abstract][Full Text] [Related]
17. Increased Dose of Inhaled Corticosteroid versus Add-On Long-acting β-Agonist for Step-Up Therapy in Asthma.
Israel E; Roche N; Martin RJ; Colice G; Dorinsky PM; Postma DS; Guilbert TW; van Aalderen WM; Grigg J; Hillyer EV; Burden A; von Ziegenweidt J; Thomas V; Price DB
Ann Am Thorac Soc; 2015 Jun; 12(6):798-806. PubMed ID: 25756308
[TBL] [Abstract][Full Text] [Related]
18. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
19. Assessing the viability of long-acting β
Matera MG; Rinaldi B; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):129-136. PubMed ID: 27615145
[TBL] [Abstract][Full Text] [Related]
20. Investigational beta-2 adrenergic agonists for the treatment of chronic obstructive pulmonary disease.
Malerba M; Radaeli A; Montuschi P; Babu KS; Morjaria JB
Expert Opin Investig Drugs; 2017 Mar; 26(3):319-329. PubMed ID: 28117615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
